Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Friederike Schumann"'
Autor:
Günther Silbernagel, Lars K. Steiner, Tim Hollstein, Günter Fauler, Hubert Scharnagl, Tatjana Stojakovic, Friederike Schumann, Bediha Bölükbasi, Winfried März, Elisabeth Steinhagen-Thiessen, Ulrich Laufs, Ursula Kassner
Publikováno v:
Journal of Lipid Research, Vol 60, Iss 1, Pp 161-167 (2019)
Very few studies have investigated the interrelations between proprotein convertase subtilisin/kexin type 9 (PCSK9) metabolism, cholesterol synthesis, and cholesterol absorption. We aimed to address this issue in a large clinical trial of 245 patient
Externí odkaz:
https://doaj.org/article/31fc2dbf5bf549d6973dc635a396a82f
Publikováno v:
Herz. 47:204-211
ZusammenfassungStatine gehören zu den bestuntersuchten Medikamenten. Aufgrund der umfangreichen Evidenz in Bezug auf Wirksamkeit und Sicherheit gehören sie zur Basis der lipidsenkenden Therapie. Während die Verträglichkeit von Statinen in den gro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05fea3b74236fd19526d207baab30f3c
https://doi.org/10.1007/s00059-022-05114-w
https://doi.org/10.1007/s00059-022-05114-w
Publikováno v:
Sensors
Volume 23
Issue 5
Pages: 2387
Volume 23
Issue 5
Pages: 2387
Emotions are indicators of affective states and play a significant role in human daily life, behavior, and interactions. Giving emotional intelligence to the machines could, for instance, facilitate early detection and prediction of (mental) diseases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::508ca3dd02a077b684723dfd0d916025
https://doi.org/10.20944/preprints202301.0156.v1
https://doi.org/10.20944/preprints202301.0156.v1
Publikováno v:
MMW - Fortschritte der Medizin. 164:16-18
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5c12df8de28e6d6ef662c4a62f08e86
https://doi.org/10.1007/s15006-022-0671-z
https://doi.org/10.1007/s15006-022-0671-z
Publikováno v:
HerzLiteratur. 47(3)
Statins are among the best studied drugs. Due to the extensive evidence regarding efficacy and safety, they are the cornerstone of lipid-lowering therapy. While the tolerability of statins in large blinded studies is at the placebo level, so-called s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::547e3411adf345d1e9cc17da7a795ef6
https://pubmed.ncbi.nlm.nih.gov/35451596
https://pubmed.ncbi.nlm.nih.gov/35451596
Autor:
Thomas Bobbert, Ursula Kassner, Elisabeth Steinhagen-Thiessen, Friederike Schumann, Thomas Grenkowitz, Tim Hollstein
Publikováno v:
American Journal of Cardiovascular Drugs
Aims Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for patients at high/very high cardiovascular risk who are inadequately treated with maximally tolerated lipid-lowering therapies (LLTs). Objectives We assessed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfd2ac892d7d43b4e4591b6d0f453aca
https://doi.org/10.1007/s40256-020-00411-3
https://doi.org/10.1007/s40256-020-00411-3
Publikováno v:
MMW - Fortschritte der Medizin. 162:54-61
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ab407d0a40aa2e172e882c66793c92c
https://doi.org/10.1007/s15006-020-0015-9
https://doi.org/10.1007/s15006-020-0015-9
Publikováno v:
MMW Fortschritte der Medizin. 164(Suppl 4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c6f3c3e1057512476bcd5e29d0294987
https://pubmed.ncbi.nlm.nih.gov/35146711
https://pubmed.ncbi.nlm.nih.gov/35146711
Autor:
Guenter Fauler, Elisabeth Steinhagen-Thiessen, Bediha Bölükbasi, Ulrich Laufs, Lars K. Steiner, Ursula Kassner, Hubert Scharnagl, Winfried März, Tim Hollstein, Tatjana Stojakovic, Guenther Silbernagel, Friederike Schumann
Publikováno v:
Journal of Lipid Research, Vol 60, Iss 1, Pp 161-167 (2019)
Very few studies have investigated the interrelations between proprotein convertase subtilisin/kexin type 9 (PCSK9) metabolism, cholesterol synthesis, and cholesterol absorption. We aimed to address this issue in a large clinical trial of 245 patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b84d59f6d89260a26add027d32c8adfc
http://www.sciencedirect.com/science/article/pii/S0022227520326730
http://www.sciencedirect.com/science/article/pii/S0022227520326730
Autor:
Friederike Schumann, Elisabeth Steinhagen-Thiessen, Stefan Coassin, Gilles Lambert, Mikaël Croyal, Clément Chong Hong-Fong, Tim Hollstein, Kévin Chemello, Thomas Grenkowitz, Brice Nativel, Claudia Lamina, Ursula Kassner, Valentin Blanchard
Publikováno v:
Cardiovascular research. 118(9)
AIMS Lipoprotein (a) [Lp(a)] is a lipoprotein species causatively associated with atherosclerosis. Unlike statins, PCSK9 inhibitors (PCSK9i) reduce Lp(a), but this reduction is highly variable. Levels of Lp(a) are chiefly governed by the size of its
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc8e03222d45de7bd0818429c9231df4
https://pubmed.ncbi.nlm.nih.gov/34314498
https://pubmed.ncbi.nlm.nih.gov/34314498